Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CΥP2D6 genotypes

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 4, 1999, Pages 402-407

  Huang, Jin Ding ^a   Chuang, Shu Kuei ^b   Cheng, Ching Ling ^b   Lai, Ming Liang ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMETOPROLOL; METOPROLOL;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG EXCRETION; ENANTIOMER; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; URINARY EXCRETION;

EID: 0032968696     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70134-7     Document Type: Article

References (28)

1. 1. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
2. 2. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
3. 3. Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988;44:431-5.
4. 4. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
5. 5. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53:410-8.
6. 6. Lou YC, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987;2:852-3.
7. 7. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
8. 8. Panserat S, Mura C, Gerard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 1994;94:401-6.
9. 9. Wang SL, Lai MD, Lai ML, Huang JD. R296C and other CYP2D6 mutations in Chinese. Pharmacogenetics 1995; 5:385-8.
10. 10. Johansson I, Oscarson M, Yu QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
11. 11. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-9.
12. 12. Dalén P, Dahl ML, Ruiz MLB, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444-52.
13. 13. McEnvoy GK, editor. American hospital formulary service drug information. Bethesda (MD): American Society of Health System Pharmacists; 1987. p. 821.
14. 14. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 1982;307:1558-60.
15. 15. Lennard MS, Silas JH, Freestone S, Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1982;14:301-3.
16. 16. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor metabolizers. Clin Pharmacol Ther 1983;34:732-7.
17. 17. Dayer P, Leemann T, Marmy A, Rosentheler J. Inter-individual variation of beta-adrenergic blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol, and metoprolol. Eur J Clin Pharamcol 1985;28:149-53.
18. 18. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphisim - population and family studies. Br J Clin Pharmacol 1985;20:555-66.
19. 19. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD. Formation of morphine from codeine in Chinese of different CYP2D6 genotypes. Clin Pharmacol Ther 1996;60:177-82.
20. 1934 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
21. 21. Straka RJ, Johnson KA, Marshall PS, Remmel RP. Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase. J Chromatogr 1990;530:83-93.
22. 22. Bahmér K, Persson A, Lagerström PO, Persson BA, Schill G. Liquid Chromatographic separation of the enantiomers of metoprolol and its alpha-hydroxy metabolite on Chiralcel OD for determination in plasma and urine. J Chromatogr 1991;553:391-7.
23. 23. Dahl ML, Yue QY, Rob HK, Johansson T, Säwe J, Sjöqvist F, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
24. 24. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin in hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996;6:441-7.
25. 25. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990;265:17209-14.
26. 26. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol pharmacokinetics in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995;58:264-8.
27. 27. Mautz DS, Shen DD, Nelson WL. Regioselectivity and enantioselectivity of metoprolol oxidation by two variants of cDNA-expressed P4502D6. Pharm Res 1995;12:2053-6.
28. 28. Murthy SS, Sherry HU, Nelson WL, Jackson PR, Lennard MS. Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. Biochem Pharmacol 1990;40:1637-44.